The phase 3 FLAURA trial (AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer) [29,30] assessed the efficacy of the third-generation EGFR inhibitor osimertinib versus the standard-of-care earlier-generation EGFR inhibitors (erlotinib, gefitinib, afatinib) as a first-line therapy in advanced EGFR mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.